Observational Post-Authorisation Study of Oxervate® (Cenegermin 20 µg/ml) eye drops in the treatment of adult patients with moderate or severe Neurotrophic Keratopathy. (DEV0118)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  Prospective patient-based data collection

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No

Procedures

No information provided.